Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study.

ABSTRACT:

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease requiring lifelong treatment, and durable medication is essential for maintaining stable glycemic control. This study aimed to evaluate the long-term efficacy of dulaglutide in participants who have continued the drug for more than one year.

Methods

We conducted a retrospective study on 605 participants, who used dulaglutide for over one year between 2016 and 2020. Changes in glycosylated hemoglobin (HbA1c), fasting plasma glucose, and bodyweight from baseline to last prescription day were assessed. Adherence was evaluated by the proportion of days covered (PDC), and a PDC value ≥ 0.80 was considered adherent.

Results

The mean age was 54.0 ± 11.1 years, and 46.1% were female. The mean basel

SUBMITTER: Kim HS 

PROVIDER: S-EPMC9659594 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature